RECRUITING

DAANCE for CHEMOTHERAPY-INDUCED NEUROPATHY

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Up to 80% of breast cancer survivors experience chemotherapy-induced neuropathy that impairs quality of life and increases fall risk long into survivorship, yet treatment options for neuropathy remain limited. The successful treatment will target neurophysiologic mechanisms for restoring function while addressing patient-reported symptoms and participation in treatment. Toward this end, the investigators propose to study a noninvasive, social sensorimotor intervention - Adapted Argentine Tango - which targets motor control restoration, symptom alleviation, and treatment participation in concert.

Official Title

DANCE-BASED AVENUES to ADVANCE NONPHARMACOLOGIC TREATMENT of CHEMOTHERAPY EFFECTS (DAANCE): a MULTICENTER TRIAL

Quick Facts

Study Start:2025-02-19
Study Completion:2025-08-15
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06749210

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Breast Cancer (BC) diagnosis of Stage I-IV including metastatic disease
  2. * completed taxane-based chemotherapy for BC at least 3 months ago (no limit on how long ago)
  3. * symptomatic for chemotherapy-induced neuropathy (self-report)
  4. * postural control score that indicates potential fall-risk
  5. * able to understand and comply with directions associated with testing and study treatments
  1. * pre-existing vestibular dysfunction
  2. * poorly controlled diabetes (hgA1C\>=8)
  3. * non-ambulatory (assistive and prosthetic devices allowed)
  4. * hearing impairment resulting in less than 10% hearing bilaterally
  5. * contraindication to participate in the experimental physical activity per the treating oncologist due to additional condition (e.g., herniated disc, unstable bone metastases)
  6. * currently in activity-based therapy (e.g., physical therapy, occupational therapy). May enroll if still meet eligibility criteria once activity-based therapy is complete.

Contacts and Locations

Study Contact

Lise Worthen-Chaudhari, PhD, MFA, CMES
CONTACT
(1) + 614-293-6281
lise.worthen-chaudhari@osumc.edu

Principal Investigator

Lise B Worthen-Chaudhari, PhD, MFA, CMES
PRINCIPAL_INVESTIGATOR
Ohio State University
Maryam B Lustberg, MD, MPH
PRINCIPAL_INVESTIGATOR
Yale University

Study Locations (Sites)

The Ohio State University
Columbus, Ohio, 43220
United States

Collaborators and Investigators

Sponsor: Ohio State University Comprehensive Cancer Center

  • Lise B Worthen-Chaudhari, PhD, MFA, CMES, PRINCIPAL_INVESTIGATOR, Ohio State University
  • Maryam B Lustberg, MD, MPH, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02-19
Study Completion Date2025-08-15

Study Record Updates

Study Start Date2025-02-19
Study Completion Date2025-08-15

Terms related to this study

Keywords Provided by Researchers

  • survivorship
  • music
  • dance

Additional Relevant MeSH Terms

  • Cancer of the Breast
  • Chemotherapy-induced Neuropathy